News ArticleAjanta Pharma Reports 33% Revenue Growth and 49% Profit Surge in Q2 FY 2027
Company posts Rs. 1,794 crore revenue and Rs. 388 crore PAT for quarter ended September 2026, driven by strong branded generics and US markets
Ajanta Pharma Limited announced a 33% increase in revenue to Rs. 1,794 crore and a 49% rise in profit after tax to Rs. 388 crore for the quarter ended September 30, 2026. The company also reported strong half-year results with a 29% revenue increase and 40% PAT growth, supported by robust performance across key markets including India, Africa, and the US generics segment.
Ajanta Pharma Limited
Financial Results
Ajanta Pharma Limited declared its consolidated unaudited financial results for the quarter and half year ended September 30, 2026, reporting a 33% increase in quarterly revenue to Rs. 1,794 crore and a 49% rise in profit after tax (PAT) to Rs. 388 crore compared to the same period last year.
Revenue growth was driven by strong performances in the India branded generics segment, Africa institutional business, and US generic pharmaceuticals, with quarter-over-quarter revenue climbs of 16%, 41%, 259%, and 41% respectively.
For the half year, Ajanta Pharma achieved revenues of Rs. 3,420 crore, up 29% against the prior year, alongside a 40% increase in PAT to Rs. 722 crore.
The company’s adjusted EBITDA, excluding forex losses, rose by 47% to Rs. 543 crore for Q2 and 34% to Rs. 997 crore for H1 FY 2027.
India branded generics exceeded the Indian Pharmaceutical Market (IPM) growth by 27%, driven primarily by new product launches and volume increases.
Ajanta Pharma’s research and development expenditure was Rs. 72 crore for Q2 FY 2027, representing 4% of revenue, reflecting ongoing investment in innovation and regulatory filings including ANDAs for the US market.
Highlights
- Q2 FY 2027 revenue at Rs. 1,794 crore, up 33% year-over-year
- Profit after tax rose 49% to Rs. 388 crore for the quarter
- Half year revenue increased 29% to Rs. 3,420 crore
- Adjusted EBITDA excluding forex loss reached Rs. 543 crore in Q2, a 47% increase
- India branded generics segment grew 23% in Q2 and outperformed IPM by 27%
- US generic revenue up 41% to Rs. 484 crore in Q2 FY 2027
Key Data Snapshot
What happened
- Ajanta Pharma released its unaudited consolidated financial results for Q2 and H1 FY 2027 ending 30 September 2026.
- The company reported significant growth in revenues and profits compared to the respective periods in FY 2026.
Financial performance
- Q2 FY 2027 revenue stood at Rs. 1,794 crore, a 33% increase from Rs. 1,354 crore in Q2 FY 2026.
- Profit after tax rose 49% to Rs. 388 crore in Q2 FY 2027 from Rs. 260 crore in Q2 FY 2026.
- Adjusted EBITDA excluding forex loss increased 47% to Rs. 543 crore in Q2 FY 2027 from Rs. 369 crore previously.
- For the half year, revenue was Rs. 3,420 crore, up 29%, and PAT was Rs. 722 crore, up 40%.
- ROCE and RONW for H1 FY 2027 were 41% and 31% respectively, indicating efficient capital utilization and profitability.
Operational performance
- Segment-wise growth included 16% increase in India branded generics revenue to Rs. 504 crore in Q2.
- Africa institutional segment grew 259% in Q2, reaching Rs. 116 crore.
- US generic segment sales rose 41% to Rs. 484 crore in Q2.
- New product launches and volume increases helped India branded generics outperform Indian Pharmaceutical Market growth by 27%.
Key details
- Ajanta Pharma filed 1 ANDA and received 4 approvals from US FDA in H1 FY 2027; 3 ANDAs launched, total commercialized ANDAs now 52.
- R&D expenditure was Rs. 72 crore for Q2 FY 2027, approximately 4% of revenue.
- The company operates 7 manufacturing facilities in India and has a state-of-the-art R&D center in Mumbai.
Next milestones
- The company scheduled an earnings conference call on 30 October 2026 to discuss the financial results in detail and field investor questions.
- The transcript of the call will be published on the company website for investor access.
Highlights
- Q2 FY 2027 revenue at Rs. 1,794 crore, up 33% year-over-year
- Profit after tax rose 49% to Rs. 388 crore for the quarter
- Half year revenue increased 29% to Rs. 3,420 crore
- Adjusted EBITDA excluding forex loss reached Rs. 543 crore in Q2, a 47% increase
- India branded generics segment grew 23% in Q2 and outperformed IPM by 27%
- US generic revenue up 41% to Rs. 484 crore in Q2 FY 2027
Disclosures
- Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Navin Fluorine International Ltd Reports ₹269.24 Crore Q2 Profit and Declares ₹8 Interim Dividend for FY2026-27
Navin Fluorine International Limited released its unaudited consolidated financial results for the quarter and half year ended September 30, 2026. The company recorded a profit after tax of ₹269.24 crore for the quarter and declared an interim dividend of ₹8 per equity share for the fiscal year 2026-27.
Read Full Story
Max Healthcare Announces Q2 FY2027 Results and ₹190 Crore Expansion for Noida and Vaishali Hospitals
Max Healthcare Institute Limited approved its unaudited financial results for the quarter and half year ended September 30, 2026, and sanctioned ₹93 crore and ₹97 crore capital expenditure for upgrading hospitals at Noida and Vaishali, respectively. The company also revised the Gurugram hospital project's cost to ₹1,143 crore with a new completion timeline of April 2027.
Read Full Story
GAIL India Reports ₹11,611.44 Crore Profit Before Tax for First Half of 2026
GAIL (India) Limited posted a profit before tax of ₹11,611.44 crore for the half year ended September 30, 2026, with total income of ₹86,116.52 crore, reflecting its continuing scale of operations. The company released its unaudited standalone financial results, which include ongoing legal matters contested with the Petroleum and Natural Gas Regulatory Board and central excise authorities.
Read Full Story
